China’s Regions Launch Coordinated Push for Brain-Computer Interface Industry
Multiple regions across China have released specialized support policies for the brain-computer interface (BCI) industry since the second quarter of 2026, signaling a coordinated national push to establish a competitive edge in this cutting-edge technology field. Tianjin, Guangdong, and Anhui have each published action plans outlining targets, key tasks, and financial support mechanisms for BCI development through 2030, as reported by People’s Daily.
A Strategic National Priority
The policy blitz follows a landmark inclusion of “brain-computer interface” in China’s 2026 Government Work Report, where it was listed alongside quantum technology, embodied intelligence, and 6G as a future industry to be cultivated. BCI is now positioned as a core track for China’s “new quality productive forces” (新质生产力) strategy, which aims to drive economic growth through technological innovation.
“Multiple regions issuing supportive policies aims to accelerate the coordinated development of BCI technology and industry, better improve future industry布局, and inject momentum into local high-quality economic and social development,” Zhang Xiaorong, Dean of the Deep Technology Research Institute, told Securities Daily, as reported via Sina Finance.
Regional Policy Breakdown
Tianjin was the first mover, issuing its “Tianjin Brain-Computer Interface Innovation Development Action Plan (2026-2030)” on May 28. The plan emphasizes financial support mechanisms including government investment funds, social capital-driven sci-tech funds, IPO support for qualified enterprises, and the issuance of sci-tech innovation bonds.
Guangdong followed on June 24 with ambitious targets: by 2027, breakthroughs in key BCI technologies and analysis of neural circuit mechanisms for five or more major brain diseases; by 2030, 100 new BCI sci-tech enterprises, 10 or more non-invasive BCI hit products, multiple invasive BCI products entering clinical trials, 200 BCI hospital wards serving over 500,000 patients, and a core industry scale reaching 100 billion yuan (approximately $13.8 billion), radiating to 1,000 billion yuan in upstream and downstream industries.
Anhui released its action plan on June 15, targeting top-tier national status in BCI technology by 2028, with leadership in electrodes, chips, and algorithms. The province has adopted a spatial layout dubbed “One Core, Two Wings” — Hefei as the innovation hub, Bengbu for sensor manufacturing, and Wuhu for clinical research. Anhui is also employing an “open competition” mechanism with up to 10 million yuan per project, as detailed by Zhongan Online.
From Lab to Market: The Commercialization Challenge
Industry experts caution that significant hurdles remain. Pan Helin, a member of the MIIT Information and Communication Economic Expert Committee, noted that many BCI innovations remain at the laboratory stage with vague application scenarios and unclear market positioning. “Local encouragement of related application product development will help promote efficient transformation of research results and clarify these issues,” he told Securities Daily.
Zheng Lei, Visiting Professor at the Shenzhen Finance Institute of the Chinese University of Hong Kong (Shenzhen), identified two critical variables for the industry’s future: electrode long-term stability and medical insurance payment openness. Industry insiders widely regard 2026 as the “first year of commercialization” for the BCI sector.
Investment Boom
The policy push coincides with a dramatic surge in BCI investment. According to IT桔子 data, as of June 30, 2026, there were 64 BCI investment and financing cases totaling 72.53 billion yuan in 2026 alone — far exceeding 2025’s full-year performance of 47 cases worth 23.98 billion yuan. The 2026 figure for just the first four months was 44.14 billion yuan, as analyzed by IT桔子 via Huxiu.
Zheng Lei noted that the continuous influx of funds provides powerful momentum for technology iteration, enterprise growth, and industry expansion.
Outlook
Experts predict that more regions will release specialized BCI policies in the second half of the year, with capital accelerating into all segments of the BCI industry chain. Zhang Xiaorong expects rapid growth in the number of BCI small and medium-sized enterprises, with funds flowing first to quality enterprises with application products. He also anticipates accelerated commercialization of BCI medical devices and potential batch launches of consumer-oriented products.
However, Zhang cautioned that key technological breakthroughs affecting the industry’s future direction will not happen overnight. The BCI industry’s ability to achieve major breakthroughs on the application end depends on core variables such as electrode stability and healthcare payment policy evolution, Zheng added.
With coordinated policy support, surging investment, and accelerating technological maturity, China’s BCI industry stands at a pivotal moment — moving from laboratory research toward real-world applications that could transform healthcare, human-computer interaction, and beyond.